In a pre-Series A financing round, Visionhealth secured three million euros from DB Speciality Invest GmbH & Co. KG. The owner of this investment company is life science entrepreneur Dietrich Bruchmann, founder and managing director of Nuvisan Pharma HoldingHe will also take a seat on Visionhealth's advisory board in the future.
The Munich-based company plans to use the raised capital to finance a second, larger study to provide decision-makers and physicians with even stronger scientific evidence for the evaluation and potential recommendation of Kata.
Basis for market access
The study, which involves approximately 120 patients suffering from chronic respiratory diseases such as asthma or COPD (chronic obstructive pulmonary disease), is designed as a randomized, controlled, multicenter trial lasting one year. It is intended to lay the foundation for Kata's market access in Germany, other EU countries, and possibly the US. At the same time, Visionhealth is working on strategic partnerships for international growth.
Kata is a Class IIa medical device-certified app that provides targeted support for people with chronic lung diseases during inhalation therapy. Correct use of the inhalation device is crucial for therapeutic success. Incorrect inhalation results in less active ingredient reaching the lungs, which can lead to a more severe course of the disease over time. Repeated training of patients on the respective inhalation devices is often not possible in practice due to a lack of resources.
“The incorrect inhalation of therapeutics can be a major error factor”
Dietrich Bruchmann, founder and CEO of the Nuvisan Pharma Holding Group, says:
"I'm excited to see how Kata's potential will unfold as access improves for asthma and COPD patients. As the head of a CRO working in the respiratory care field, I was also fascinated by the use of the Kata Clinical app in clinical trials: Incorrect inhaled uptake of therapeutics can be a major error factor. Using the app to support each patient individually in using the inhaler correctly will not only improve the patient's daily outcomes but also the quality of clinical trial results, thus ensuring maximum benefit from the therapy."
Sabine Häußermann, CEO and founder of Visionhealth, adds:
“We are pleased to be able to combine the very positive results we received from our feasibility study with further data on the efficiency of Kata With over 2,400 users since its initial launch, an impressive 83.3 percent have told us they would continue to use the Kata app; a similar number of users would recommend the app to friends with respiratory conditions. It's truly gratifying to see how we can make a difference for patients and improve health outcomes. We greatly appreciate the continued support of our shareholders and our new investor, Dr. Buchmann of Nuvisan!
